Copyright
©2008 The WJG Press and Baishideng.
World J Gastroenterol. Dec 21, 2008; 14(47): 7175-7182
Published online Dec 21, 2008. doi: 10.3748/wjg.14.7175
Published online Dec 21, 2008. doi: 10.3748/wjg.14.7175
Table 4 Cell cycle of HepG2 treated with GABA at serial concentrations (mean ± SD)
| 0μmol/L | 1μmol/L | 10μmol/L | 20μmol/L | 40μmol/L | 60μmol/L | |
| G1/G0% | 59.7 ± 3.82 | 58.5 ± 3.63 | 55.6 ± 3.46 | 56.5 ± 3.69 | 45.2 ± 3.07 | 57.6 ± 3.83 |
| G2/M% | 13.5 ± 1.14 | 18.6 ± 1.27 | 12.5 ± 1.15 | 7.6 ± 0.79 | 17.3 ± 1.48 | 12.7 ± 1.53 |
| S%1 | 27.2 ± 2.19 | 31.3 ± 2.24 | 32.4 ± 2.58 | 35.8 ± 2.47 | 37.6 ± 2.64 | 30.4 ± 2.32 |
- Citation: Liu Y, Li YH, Guo FJ, Wang JJ, Sun RL, Hu JY, Li GC. Gamma-aminobutyric acid promotes human hepatocellular carcinoma growth through overexpressed gamma-aminobutyric acid A receptor α3 subunit. World J Gastroenterol 2008; 14(47): 7175-7182
- URL: https://www.wjgnet.com/1007-9327/full/v14/i47/7175.htm
- DOI: https://dx.doi.org/10.3748/wjg.14.7175